Vietnam is entering a new era of precision oncology as hospitals, diagnostic laboratories and biotechnology companies increasingly adopt cancer biomarker testing to enable earlier diagnosis, personalised treatment and improved patient outcomes. Advances in molecular diagnostics, next-generation sequencing (NGS) and liquid biopsy technologies are transforming the way cancer is detected and managed, positioning biomarkers at the centre of modern cancer care.
Although there is currently no dedicated published valuation for Vietnam's Cancer Biomarkers Market, industry analysis indicates the sector is worth an estimated US$42–55 million in 2025 and could grow to US$85–115 million by 2030. Growth is being driven by increasing cancer incidence, expanding genomic testing capabilities and wider adoption of precision medicine across Vietnam's healthcare system.
Cancer biomarkers are measurable biological characteristics—including genes, proteins and other molecular signatures—that help clinicians diagnose cancer, assess prognosis, predict response to therapy and monitor disease progression. They have become fundamental to precision medicine by enabling treatments to be tailored to the molecular profile of each patient's tumour.
The market encompasses a broad range of technologies and applications, including:
- Companion diagnostics
- Liquid biopsy
- Genomic biomarkers
- Proteomic biomarkers
- Circulating tumour DNA (ctDNA)
- Tumour mutation profiling
- Immunotherapy biomarkers
- Predictive biomarkers
- Prognostic biomarkers
- Next-generation sequencing (NGS)-based testing
Vietnam is experiencing a growing cancer burden, creating greater demand for advanced diagnostic technologies. Lung, liver, breast, colorectal and gastric cancers remain among the country's most prevalent cancers, increasing the need for earlier detection and more personalised treatment strategies. Precision diagnostics are enabling clinicians to identify actionable genetic mutations that guide targeted therapies and improve treatment outcomes.
The country's investment in genomics is also supporting market growth. Vietnamese hospitals and research centres are expanding molecular pathology and genomic sequencing capabilities, while local biotechnology companies are developing innovative cancer testing solutions. One notable example is Gene Solutions, whose genomic oncology portfolio includes multi-cancer early detection, companion diagnostics and personalised cancer monitoring technologies that are increasingly being deployed across Southeast Asia.
Liquid biopsy represents one of the fastest-growing segments of the market. Unlike traditional tissue biopsies, liquid biopsy analyses circulating tumour DNA from a simple blood sample, allowing clinicians to detect genetic mutations, monitor treatment response and identify disease recurrence using minimally invasive techniques. As sequencing technologies become faster and more affordable, liquid biopsy is expected to become an increasingly important component of routine cancer management.
Artificial intelligence is further enhancing cancer biomarker research. AI-powered bioinformatics platforms are helping researchers analyse complex genomic datasets, identify novel biomarkers and improve the interpretation of sequencing results. Combined with cloud computing and advanced analytics, these technologies are accelerating biomarker discovery while supporting more accurate clinical decision-making.
The Asia-Pacific region continues to be one of the world's fastest-growing markets for cancer biomarkers, driven by rising cancer incidence, expanding molecular diagnostics infrastructure and increasing investment in precision medicine. Governments across the region are strengthening national cancer programmes while encouraging wider adoption of genomic testing and companion diagnostics, trends that are expected to support continued growth in Vietnam over the coming decade.
Globally, the cancer biomarkers market continues to expand rapidly as pharmaceutical companies increasingly develop targeted therapies that require companion diagnostic testing. Growth is being driven by advances in genomics, immuno-oncology, next-generation sequencing and personalised medicine, with biomarkers becoming essential throughout the cancer care pathway—from early detection through to treatment selection and long-term disease monitoring.
Leading companies operating in the global cancer biomarkers market include Roche Diagnostics, Thermo Fisher Scientific, QIAGEN, Illumina, Agilent Technologies, Abbott, Guardant Health, Exact Sciences, Bio-Rad Laboratories, Danaher (Beckman Coulter Life Sciences), Foundation Medicine and Myriad Genetics. These organisations continue to invest heavily in companion diagnostics, liquid biopsy, genomic sequencing and AI-powered biomarker discovery.
As Vietnam continues to strengthen its oncology services and expand precision medicine programmes, cancer biomarkers are expected to become an increasingly important component of clinical practice. For diagnostic manufacturers, sequencing technology providers, biotechnology companies, pharmaceutical organisations, laboratory equipment suppliers and digital pathology innovators, Vietnam represents one of Southeast Asia's most promising emerging markets for precision oncology.